Web Research
Web Research
The single most important finding from the web that the filings don't fully convey: analyst consensus has dramatically diverged, with price targets ranging from $32 to $75 — the widest spread in CNC's coverage history. The Q1 2026 earnings beat and guidance raise are catalyzing upgrades, but bears remain entrenched on Medicaid policy risk and the fragility of the margin recovery. The stock's 64% rally from March lows happened before most sell-side targets were updated.
What Matters Most
Analyst Consensus Target
Low Target
High Target
Current Price
CNC already trades above the analyst consensus target of $47.42. The stock has moved faster than sell-side coverage, meaning either the consensus is stale (likely given the Q1 beat) or the market is pricing in a more aggressive recovery than analysts expect.
Miller Value Funds highlighted CNC as a holding, noting management sees Medicaid growing at a 6–7% CAGR long-term with potential near-term segment profitability inflection. Their thesis emphasizes CNC's largest D-SNP concentration among peers as a structural advantage.
Q1 2026 beat changed the narrative. The $3.37 adjusted EPS (vs. expectations around $2.90) and guidance raise to more than $3.40 (from more than $3.00) triggered the April 28 rally. Management's comment that they'd be "disappointed" if Medicaid HBR only hits 93.7% signaled confidence in further margin improvement beyond guidance.
Cantor Fitzgerald downgrade to $38 (July 2025) was the sentiment nadir. The downgrade came during the Q3 2025 impairment disclosure and Marketplace volatility. Multiple brokers have been slower to upgrade despite the Q1 2026 beat.
Jefferies previously had an underperform rating — one of the more bearish sell-side views. The dispersion between the $32 low and $75 high target reflects genuine uncertainty about whether the margin recovery is cyclical normalization or a fundamental turn.
Forbes Best Employers recognition is a soft signal that the London leadership team is stabilizing culture after the Neidorff-era governance concerns and the massive stock price decline.
Recent News Timeline
What the Specialists Asked
Warren (Business): CNC's Medicaid market share by state is difficult to verify externally with precision. Web sources confirm CNC is the largest Medicaid MCO nationally, with Florida and New York as the two largest state contracts (each over 10% of Medicaid premium revenue). The competitive threat from Molina (MOH) in overlapping states is real but limited by MOH's smaller scale.
Quant (Numbers): Analyst consensus for FY2026 EPS averages $3.40–3.50 based on available web data, closely aligned with the revised guidance. FY2027 consensus is not yet widely available but early estimates suggest $5.00+ if margin recovery continues.
Forensic (Financial Shenanigans): No SEC investigations, auditor resignations, restatements, or short-seller reports were found in web research. The goodwill impairment was the subject of investor concern but was triggered by a standard quantitative test, not discretionary.
Sherlock (People): Sarah London has received mixed reviews from analysts and investors — praised for operational focus and cultural transformation, criticized for the FY2025 Marketplace miss. No personal controversies were found. Politan Capital, an activist firm, had previously engaged with CNC around the Neidorff succession but appears to have exited.
Historian (Story): The WellCare acquisition ($17B, 2020) is increasingly viewed as an overpayment — the $6.7B goodwill impairment in FY2025 confirms that the acquired value was not fully realized. However, the operational footprint (30 states, largest PDP) provides enduring competitive scale.
Manifest Summary
The web research corroborates the specialist analysis: CNC is a margin-recovery story with genuine operational improvement underneath the GAAP noise. The key external risk the filings understate: the OBBBA's Medicaid provisions (work requirements, provider tax changes beginning 2028) represent a structural policy headwind that could limit the ceiling on Medicaid margins even as HBR normalizes. The key external positive: the market has moved faster than sell-side coverage, suggesting institutional buyers are building positions ahead of consensus upgrades.